<sentence id="0">Tyloxapol inhibits NF-kappa B and cytokine release , scavenges HOCI , and reduces viscosity of cystic fibrosis sputum .</sentence>
<sentence id="1">Cystic fibrosis ( CF ) patients develop progressive cytokine-mediated inflammatory lung disease , with abundant production of thick , tenacious , protease- and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy .</sentence>
<sentence id="2">In the search for a potential treatment , we have tested tyloxapol , an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis .</sentence>
<sentence id="3">Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B ( NK-kappa B ) , reduces resting secretion of the cytokine interleukin-8 ( IL-8 ) in cultured human monocytes , and inhibits lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor-alpha ( TNF-alpha ) , IL-1 beta , IL-6 , IL-8 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , and the eiconsanoids thromboxane A2 and leukotriene B4 ( LTB4 ) .</sentence>
<sentence id="4">We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH ) .</sentence>
<sentence id="5">Tyloxapol ( 0.05 to 0.1 % wt/vol ) effectively scavenges the oxidant hypochlorous acid ( HOCl ; 1 to 7.5 mM ) in vitro , and protects from HOCl-mediated lung injury in rats .</sentence>
<sentence id="6">Tyloxapol also reduces the viscosity of CF sputum ( from 463 +/- 133 to 128 +/- 52 centipoise ) .</sentence>
<sentence id="7">We conclude that tyloxapol is <scope type="spec" id="0"> <cue type="spec" id="0">potentially</cue> useful as a new antiinflammatory therapy for CF lung disease</scope> , and <scope type="spec" id="1"> <cue type="spec" id="1">could</cue> <scope type="spec" id="2"> <cue type="spec" id="2">possibly</cue> promote clearance of secretions in the CF airway</scope></scope> .</sentence>